Ann: Ceasing to be a substantial holder, page-6

First 6 Last

Share
Profile

Follow
Brightoil

5,071 Posts.

789

18/07/20

10:52

Post #: 45953210
Share

Originally posted by Herpzanederp: ↑

If you look at the fall last week anyway, it was a market direction led fall. Not one specific to PushPay.
Sometimes its easy to get swayed and develop false hypotheses and that's why I start every day by opening up NASDAQ and us futures and looking a the trend before even eyeing my investments.

The BNPL and other tech's were hit hard too. Sometimes it's easy to read into why institutions do x y or z but it's important imo to stay objective and focus on the business and to make the hard decision of capitalising on weakness when it is heavily market direction led.

If PPH had exhibited isolated weakness in disconnection with the general NASDAQ/Tech market then I would have waited a little more before topping up, but I decided to pick some more up at the NZD 7.80$ range on friday as I am happy holding this long for atleast another FY

Institutions don't really sell or buy at the best times either, but looks like JP decided to underwrite and then exit, but like you said they clearly exited to sell to a new institution probably and if there is no notice I will conclude it was to an already exisiting substantial holder.

Expand

They must be a lot more selling as ots underwritten. Imo more stock left to dump. This is going to $6 IMO. Bnpl is the new dot com. Plus cash is low so a cap adding is a coming. if in recession no one will have money to donate

PPH Price at posting: $7.50 Sentiment: Sell Disclosure: Not Held
Upvote

0 Great analysis

Reply

Top Stories

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03